A Phase I/IIa, Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Moderate Alzheimer's Disease
Latest Information Update: 14 May 2025
At a glance
- Drugs Troculeucel (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors NKGen Biotech
Most Recent Events
- 07 May 2025 According to a NKGen Biotech media release, data from the phase 1 part of this phase 1/2a trial will be presented at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which will take place in New Orleans, Louisiana from May 13-17, 2025.
- 14 Apr 2025 According to a NKGen Biotech media release, data from this trial will be presented at the at the 7th China International Biotechnology Conference & Exhibition (BIOTEC-CHINA 2025), to be held in Beijing, China, April 16-18, 2025.
- 07 Apr 2025 According to a NKGen Biotech media release, Clinical development of troculeucel is ongoing and will be evaluated for safety and efficacy in the randomized, placebo-controlled Phase 2a part of the study.